Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Basic & Clinical Pharmacology & Toxicology|January 7, 2010
On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic modelsPhilip J Lowe, Stacey Tannenbaum, Kai Wu, et al.Journal of Clinical Pharmacology|December 14, 2011
Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575Xiaoyu Yan, Philip J Lowe, Martin Fink, et al.Clinical Pharmacokinetics|May 4, 2012
Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibodyAbhijit Chakraborty, Stacey Tannenbaum, Christiane Rordorf, et al.The Journal of Allergy and Clinical Immunology|January 10, 2009
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrationsRaymond G Slavin, Caterina Ferioli, Stacey J Tannenbaum, et al.The Journal of Allergy and Clinical Immunology. in Practice|September 13, 2014
Omalizumab in asthma: an update on recent developmentsMarc Humbert, William Busse, Nicola A Hanania, et al.The Journal of Allergy and Clinical Immunology|May 18, 2016
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responsesGail M Gauvreau, Jonathan P Arm, Louis-Philippe Boulet, et al.Pageof 2